Laccure's Antibiotic-Free OTC Product for Bacterial Vaginosis Ready for Commercialisation

PR61600

HELSINGBORG, Sweden, Sept. 1 /PRN=KYODO JBN/ --

    The Swedish company Laccure AB has developed a breakthrough women's health

product that is effective, safe and user-friendly. Laccure's owners are now

aiming to divest the company to a buyer with appropriate resources to launch

the product.

    The manufacturing process for the new product, Laccure(R) Pessary, has now

been scaled up and the product is ready for market introduction. Laccure has

therefore initiated a search for an established company interested in acquiring

Laccure and launching the product. Evli Corporate Finance is retained for the

exit process.

    "We are proud to announce that the final development stage, the up-scaling

of the manufacturing process for Laccure(R) Pessary, our new antibiotic-free,

non-prescription product for the treatment and prevention of bacterial

vaginosis, is now completed. The product is thus ready for launch. Our

objective from the start of the project has been to sell Laccure to a company

that will take the product to market," says Dr Jeanette Robertsson, CEO of

Laccure AB.

    Bacterial Vaginosis

    Bacterial vaginosis (BV) is the most common vaginal infection in women of

childbearing age, affecting more than 300 million women worldwide each year.

Today, there is a lack of effective and safe products that are also

user-friendly and can be dosed with low frequency. Women are often embarrassed

at having BV and their quality of life is negatively affected. BV is an

imbalance of naturally occurring vaginal bacterial flora, resulting in a lack

of vaginal acidity, discharge with a pronounced foul odour and inhibition of

normal lactobacilli growth. Frequent recurrences are common.

    Laccure(R) Pessary

    The new, patented product is based on a proprietary substance that releases

lactic acid over several days to decrease the elevated vaginal pH. The

development work has focused on creating a user-friendly, non-smear product

that is easy to insert and highly effective. This has been demonstrated in

clinical studies, in which 80% of the women were free of their BV after a

single dose. Laccure(R) Pessary need only be administered once a month to

prevent recurrence. Laccure(R) Pessary is CE-marked as a Class IIa medical

device and is now ready for market introduction in the EU/EES countries.

    Laccure AB  

    Laccure AB was founded in 2007 and is a project company within P.U.L.S.

http://www.laccure.com and http://www.pulsinvest.se

    Source: Laccure AB